Abstract
BackgroundMultidrug-resistant tuberculosis (MDRTB) remains a health problem for many countries in the world. The share of MDRTB is 10–30% among newly diagnosed cases and 20–70% among relapses and treatment failure. The aim of the study is to define the side effects of second line drugs used in the treatment of MDRTB on thyroid function.MethodsIn 30 patients with multidrug resistant tuberculosis, echostructure of thyroid was studied by ultrasound imaging method. Indices of thyroid function: plasma levels of free thyroxin, thyroid stimulating hormone were studied before chemotherapy initiated, at the end of intensive phase and after the treatment finished.ResultsDecreasing of thyroid function under antituberculosis chemotherapy was approved. Monitoring and correction of thyroid function during antituberculosis chemotherapy was suggested.ConclusionPatients with MDRTB taking ethionamide and PAS are at increased risk for hypothyroidism and goiter, and therefore require monitoring of thyroid function at all stages of antituberculosis chemotherapy for its timely correction.
Highlights
Multidrug-resistant tuberculosis (MDRTB) remains a health problem for many countries in the world
A pathology of the thyroid gland was revealed in the study of its ultrasound; 2 (6,67%) - its goiter transformation, in 5 (16,67%) – diffusely enlarged thyroid with the presence of hypoechoic micronodules (1–6 mm) with surrounding echogenic septations and in others -signs of diffused pathology in the form of granularity of its structure, containing areas of normal, increased and decreased echogenicity, which is characteristic of autoimmune thyroiditis
The data obtained indicates a significant weakening of thyroid function in Multidrug-resistant tuberculosis (MDR TB) patients under the influence of individual chemotherapy with the inclusion of ethionamide and Para-aminosalicylic acidA (PAS)
Summary
Multidrug-resistant tuberculosis (MDRTB) remains a health problem for many countries in the world. The share of MDRTB is 10–30% among newly diagnosed cases and 20–70% among relapses and treatment failure. The aim of the study is to define the side effects of second line drugs used in the treatment of MDRTB on thyroid function. Multidrug-resistant tuberculosis (MDR TB) remains a health problem for many countries in the world [1, 2]. The share of MDR TB is 10–30% among newly diagnosed cases and 20–70% among relapses and treatment failure [3]. Treatment of these cases demands a 20-month chemotherapy regimen which includes 8 months of intensive phase. Real study is undertaken as a prospective one to illuminate unclear points of the problem previously discussed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
